Form 4: PharmaCyte Director Abecassis Reports Equity Changes

PharmaCyte Biotech Director Michael M. Abecassis reported the acquisition of common stock and stock options, alongside shares withheld for tax liability.

Summary

• Michael M. Abecassis, a Director of PharmaCyte Biotech, Inc. (PMCB), reported changes in his beneficial ownership of company securities.
• On December 12, 2025, Mr. Abecassis acquired 37,500 shares of common stock at a price of $0 per share.
• Concurrently, 16,875 shares of common stock were disposed of at a price of $1.02 per share to satisfy tax liability upon the vesting of restricted stock units.
• Following these transactions, Mr. Abecassis directly owns 22,292 shares of common stock and indirectly owns 800 shares through Transplant Consulting LLC.
• On April 25, 2025, Mr. Abecassis acquired 63,233 stock options with an exercise price of $1.22 per share.
• These stock options become exercisable on April 25, 2025, and expire on April 24, 2035.
• The 63,233 stock options will vest in full on the date of the Issuer's next annual meeting of stockholders, subject to Mr. Abecassis's continued service.
• The filing of this transaction was late due to an inadvertent administrative error.

Sentiment

Score: 6

Explanation: The filing indicates a director's increased equity stake through compensation, which is generally positive for alignment, but also notes a late filing due to administrative error.

Positives

• A Director, Michael M. Abecassis, increased his equity stake in PharmaCyte Biotech through the acquisition of common stock and stock options, aligning his interests with shareholders.
• The acquisition of 63,233 stock options provides a long-term incentive for the director, with an expiration date in 2035.

Negatives

• 16,875 shares of common stock were withheld by the Issuer to cover tax liabilities, representing a reduction in direct beneficial ownership.
• The transaction filing was late due to an administrative error, which can sometimes raise questions about internal controls, although it was attributed to an inadvertent error and not Mr. Abecassis.

Risks

• The vesting of the 63,233 stock options is subject to Mr. Abecassis's continued service to the company until the next annual meeting of stockholders.
• The late filing of the transaction, even if due to an administrative error, highlights a potential risk in internal compliance procedures for SEC reporting.

Future Outlook

The 63,233 stock options granted to Mr. Abecassis are set to vest in full on the date of PharmaCyte Biotech's next annual meeting of stockholders, contingent upon his continued service to the company.

Management Comments

• The transaction was late due to an inadvertent administrative error and not any error of Mr. Abecassis.

Industry Context

Form 4 filings are standard disclosures for insiders reporting changes in their beneficial ownership of company securities. These transactions often reflect compensation, personal investment decisions, or tax-related events, and are routinely monitored by investors for insights into management's alignment and sentiment.

Stakeholder Impact

• Shareholders may view the director's increased equity as a positive sign of alignment with company performance and long-term strategy.
• The late filing, while attributed to an administrative error, could prompt minor scrutiny from regulatory bodies regarding compliance procedures.

Next Steps

• The 63,233 stock options will vest in full on the date of the Issuer's next annual meeting of stockholders, subject to Mr. Abecassis's continued service.

Key Dates

Keywords

PharmaCyte Biotech, PMCB, Form 4, Insider Transaction, Stock Options, Common Stock, Beneficial Ownership, Director Compensation, Equity Grant